Handelsbanken Fonder AB Purchases 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Handelsbanken Fonder AB lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 130.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 380,000 shares of the company's stock after buying an additional 215,000 shares during the period. Handelsbanken Fonder AB owned about 0.66% of Structure Therapeutics worth $6,578,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics in the fourth quarter worth about $34,000. Virtus ETF Advisers LLC raised its stake in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares during the period. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after buying an additional 953 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after acquiring an additional 3,549 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Citigroup started coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright decreased their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has an average rating of "Buy" and an average target price of $76.50.

Structure Therapeutics Stock Down 2.4%

GPCR stock traded down $0.54 during midday trading on Friday, hitting $21.68. The company's stock had a trading volume of 669,777 shares, compared to its average volume of 856,083. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $53.45. The company has a 50 day moving average of $22.49 and a two-hundred day moving average of $24.76. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -29.30 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). On average, analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.